Trial · NCT03820388
Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia
NCT03820388, Phase 4, Completed, University of California, Davis; results first posted 2021-02-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia. Trials, record NCT03820388. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03820388
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia
- NCT number
- NCT03820388
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 75 participants, actual
- Lead sponsor
- University of California, Davis
- Conditions
- Surgery
- Interventions
- Propofol 2mg/kg, Etomidate 0.3 mg/kg, Propofol 1 mg/kg, Etomidate 0.15 mg/kg
- First posted
- 2019-01-29
- Last updated
- 2021-02-23
- Results first posted
- 2021-02-23
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Blood Pressure | 10 minutes after induction (intraoperative) | Blood Pressure Fluctuations during Induction; change of blood pressure from baseline from induction to 10 min after induction. |
| Primary | Heart Rate | 10 minutes after induction (intraoperative) | Heart Rate changes during induction (Beats Per min) |
| Secondary | Pain at Injection Site | intraoperative | Pain on injection will be measured using 4 graded scale; 0 = no pain, 1 = verbal complaint of pain, 2 = withdrawal of arm, 3 = both verbal complaint and withdrawal of arm. |
| Secondary | Myoclonic Movements | intraoperative | The incidence and degree of myoclonic movements also recorded as follows: 0 = no myoclonic movements, 1 = minor myoclonic movements, 2 = moderate myoclonic movements, 3 = major myoclonic movements. |
| Secondary | Post-operative Nausea and Vomiting | 24 hours post-operation | Presence of post-operative nausea or vomiting (yes/no). |
| Secondary | Sedation Depth | 30 minutes post-induction | Sedation depth using bispectral index (BIS). BIS scores range from 0-100. A value of 0 indicates no EEG activity, 40-60 indicates an appropriate level of general anesthesia, and 90-100 is typical of a state of wakefulness. |
| Secondary | Eyelash Reflex Disappear Time | Post induction, up to 1 hour | Time to disappearance of eyelash reflex after induction. |
| Secondary | Intubation Time | Up to 2 hours | Duration of orotracheal intubation. |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Blood Pressure | 10 minutes after induction (intraoperative) | mmHg | MEAN | |
| PRIMARY | Heart Rate | 10 minutes after induction (intraoperative) | bpm | MEAN | |
| SECONDARY | Pain at Injection Site | intraoperative | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Myoclonic Movements | intraoperative | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Post-operative Nausea and Vomiting | 24 hours post-operation | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Sedation Depth | 30 minutes post-induction | units on a scale | MEAN | |
| SECONDARY | Eyelash Reflex Disappear Time | Post induction, up to 1 hour | minutes | MEAN | |
| SECONDARY | Intubation Time | Up to 2 hours | minutes | MEAN |
Source ClinicalTrials.gov
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Blood Pressure | Propofol Group | 105 | Standard Deviation 16 | mmHg | |
| Blood Pressure | Etomidate Group | 122 | Standard Deviation 23 | mmHg | |
| Blood Pressure | Propofol Plus Etomidate Group | 117.88 | Standard Deviation 18 | mmHg | |
| Heart Rate | Propofol Group | 77 | Standard Deviation 17 | bpm | |
| Heart Rate | Etomidate Group | 74 | Standard Deviation 12 | bpm | |
| Heart Rate | Propofol Plus Etomidate Group | 74 | Standard Deviation 11 | bpm | |
| Pain at Injection Site | Propofol Group | 7 | Participants | ||
| Pain at Injection Site | Etomidate Group | 0 | Participants | ||
| Pain at Injection Site | Propofol Plus Etomidate Group | 0 | Participants | ||
| Myoclonic Movements | Propofol Group | 1 | Participants |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Propofol Group | 25 | |
| Overall Study | STARTED | Etomidate Group | 25 | |
| Overall Study | STARTED | Propofol Plus Etomidate Group | 25 | |
| Overall Study | COMPLETED | Propofol Group | 25 | |
| Overall Study | COMPLETED | Etomidate Group | 25 | |
| Overall Study | COMPLETED | Propofol Plus Etomidate Group | 25 | |
| Overall Study | NOT COMPLETED | Propofol Group | 0 | |
| Overall Study | NOT COMPLETED | Etomidate Group | 0 | |
| Overall Study | NOT COMPLETED | Propofol Plus Etomidate Group | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Propofol Group | 0 | 25 |
| Total, all-cause mortality | Etomidate Group | 0 | 25 |
| Total, all-cause mortality | Propofol Plus Etomidate Group | 0 | 25 |
| Total, other adverse events | Propofol Group | 0 | 25 |
| Total, other adverse events | Etomidate Group | 0 | 25 |
| Total, other adverse events | Propofol Plus Etomidate Group | 0 | 25 |
| Total, serious adverse events | Propofol Group | 0 | 25 |
| Total, serious adverse events | Etomidate Group | 0 | 25 |
| Total, serious adverse events | Propofol Plus Etomidate Group | 0 | 25 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03820388
GET https://conductscience.org/api/trials/v1/NCT03820388/results?page=2